SAN CLEMENTE, California, December 1, 2016 – ICU Medical, Inc. (NASDAQ: ICUI) today announced the launch of the all new Diana™ compounding workflow system. Diana is the first and only system to combine automated compounding and IV workflow technologies with wireless pharmacist notification. The Diana system allows hospital pharmacists to remotely verify the accuracy of each patient preparation on a handheld tablet display without having to gown up and enter the cleanroom.
The Diana system consists of technician and pharmacist tablets that communicate wirelessly between each other and the automated compounding module, as well as integrated high-definition cameras to let pharmacists remotely visualize the workflow ChemoLock® or ChemoClave® closed system transfer devices (CSTDs) to help hospitals comply with United States Pharmacopeial Convention (USP) Chapter <800> recommendations for the safe compounding of hazardous drugs.1,2
The compact system also fits inside an existing three-foot biological safety cabinet, helping customers avoid reconfiguring their cleanroom to incorporate large, costly robotics.
In addition, ICU Medical announced it has entered into a development partnership with leading hospital pharmacy application development company MedKeeper to allow the Diana system to communicate with MedKeeper’s PharmacyKeeperTM IV workflow system. Once available, this combined offering will provide customers with the only single solution for automated compounding with electronic medical record (EMR) connectivity, medication tracking, e-documentation for USP <797> and <800> quality assurance, and staff competency management.
“The all new Diana compounding workflow system and our partnership with MedKeeper underscore ICU Medical’s commitment to on-going innovation in pharmacy compounding,” explained Alison Burcar, vice president and general manager of ICU Medical’s infusion therapy business. “We are committed to meeting the needs of this important market with products and services that help to minimize errors and maximize drug compounding efficiency and safety.”
1 USP General Chapter <800>: Hazardous Drugs – Handling in Healthcare Settings. U.S. Pharmacopeial Convention Pharmacopeial Forum (PF).
2 Consumables pending FDA 510(k) clearance. Not available for commercial sale in the United States.